Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00117156
Status:
COMPLETED
Last Update Posted:
2016-08-01
First Post:
2005-06-30
Brief Title:
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkins Lymphoma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
03-294
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Jennifer R Brown MD PhD
Responsible Party Title:
Assistant Professor of Medicine
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Biogen | INDUSTRY |
| Beth Israel Deaconess Medical Center | OTHER |
| Massachusetts General Hospital | OTHER |
| University of Rochester | OTHER |
| Genentech Inc | INDUSTRY |